Join Growin Stock Community!

Forte biosciences, inc.FBRX.US Overview

US StockHealthcare
(No presentation for FBRX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

FBRX AI Insights

FBRX Overall Performance

FBRX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

FBRX Recent Performance

-3.74%

Forte biosciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

FBRX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

FBRX Key Information

FBRX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

FBRX Profile

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Price of FBRX

FBRX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

FBRX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
4.34
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
4.34
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is FBRX's latest earnings report released?

    The most recent financial report for Forte biosciences, inc. (FBRX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating FBRX's short-term business performance and financial health. For the latest updates on FBRX's earnings releases, visit this page regularly.

  • How much cash does FBRX have?

    At the end of the period, Forte biosciences, inc. (FBRX) held Total Cash and Cash Equivalents of 93.41M, accounting for 0.96 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is FBRX's EPS continuing to grow?

    According to the past four quarterly reports, Forte biosciences, inc. (FBRX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.99. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of FBRX?

    Forte biosciences, inc. (FBRX)'s Free Cash Flow (FCF) for the period is -14.06M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 72.81% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of FBRX?

    The latest valuation data shows Forte biosciences, inc. (FBRX) has a Price-To-Earnings (PE) ratio of -3.41 and a Price/Earnings-To-Growth (PEG) ratio of -1.21. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.